Ultragenyx agrees to sell pediatric drug-review voucher for $203 million
Ultragenyx Pharmaceutical agreed on October 14, 2026 to transfer a Rare Pediatric Disease Priority Review Voucher for $203 million. The voucher was generated by FDA approval of FAYUVI for mucopolysaccharidosis type IIIA, and the transaction followed another Ultragenyx voucher deal earlier in the same week. Completion depends on customary conditions, including the expiration of the applicable Hart-Scott-Rodino waiting period.
Why it matters
The transaction would give Ultragenyx non-dilutive cash without issuing shares, subject to closing. CFO Howard Horn said the proceeds are intended to support development of rare-disease treatments and the company’s path to profitability.
Key facts
- 1Ultragenyx’s agreed consideration for the voucher is $203 million. stocktitan.net
- 2The voucher was obtained after FDA approval of FAYUVI for mucopolysaccharidosis type IIIA, also called Sanfilippo syndrome Type A. investing.com
- 3Closing requires customary conditions, including expiration of the applicable Hart-Scott-Rodino antitrust waiting period. stocktitan.net
- 4Jefferies LLC is Ultragenyx’s exclusive financial adviser, while Gibson, Dunn and Crutcher LLP is providing legal counsel. stocktitan.net
Open questions
- The company’s release describes a signed agreement that still requires closing conditions, while some reports describe the voucher as already sold; completion status is therefore not consistently reported.
- The buyer is not identified in the available materials.
Summary written by AlphAI AI Desk from 10 of 10 sources. Not investment advice. Figures are as stated by the linked sources.